UBS Initiates Coverage on Becton, Dickinson and Company (BDX) with Buy

Market Context

Becton, Dickinson and Company operates in the Healthcare sector. The stock currently trades at $166.34 with a market capitalization of $57.4B. The stock has declined 17.7% over the past 52 weeks.

Analyst coverage from UBS provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Becton, Dickinson and Company.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Becton, Dickinson and Company

Among the 10 most recent ratings: 6 Buy, 4 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jul 28, 2026	UBS	Buy	N/A
Jul 06, 2026	Evercore ISI Group	Outperform	N/A
May 11, 2026	Barclays	Overweight	N/A
May 08, 2026	Wells Fargo	Equal-Weight	N/A
May 04, 2026	TD Cowen	Hold	N/A

Related Tools: Analyst Ratings Dashboard | View BDX Stock Page